Amgen Expects At-Risk CERA Launch, But Says Swiss Gamble Won’t Pay Off
Executive Summary
After failing to block the importation of pegylated erythropoietin, Amgen anticipates Roche will launch its continuous EPO receptor activator Mircera at risk
You may also be interested in...
Amgen On The Offensive Against Roche’s EPO Mircera; Questions Safety Data
Amgen is continuing its offensive against Roche's pending EPO product Mircera by signing an exclusive supply contract with a large dialysis provider and criticizing Roche's clinical trial program for the continuous erythropoietin receptor activator
Amgen On The Offensive Against Roche’s EPO Mircera; Questions Safety Data
Amgen is continuing its offensive against Roche's pending EPO product Mircera by signing an exclusive supply contract with a large dialysis provider and criticizing Roche's clinical trial program for the continuous erythropoietin receptor activator
Mircera EPO Will Benefit From Lower Admin Costs Of Monthly Dosing – Roche
Monthly dosing for Roche's continuous erythropoietin receptor activator Mircera may make it attractive to providers because of the lower costs of administration associated with the extended dosing regimens, according to Pharmaceutical Division CEO William Burns